【摘要】 目的探讨乳腺癌病人肿瘤组织中分子生物学标记物的表达与含蒽环类新辅助化疗有效率的关系。方法检测复旦大学附属肿瘤医院2000年1月至2006年8月173例乳腺癌新辅助化疗病人化疗术前或术后标本中ER、PR、Her-2/neu等15种分子标记物的表达情况,分析这些分子标记物的表达在新辅助化疗中的疗效预测价值。结果nm23或Cathepsin-D阴性病人化疗疗效显著优于阳性病人,多因素回归分析提示Cathepsin-D是独立的新辅助化疗疗效预测指标。结论Cathepsin-D可能作为乳腺癌新辅助化疗(蒽环类)敏感性的独立预测指标。更多还原

【Abstract】 Objective To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy.Methods Post-operative paraffin-embedded tumor samples from 173 breast cancer patients were examined for expression of ER、PR、Her-2/neu、and other 15 markers by immunohistochemistry,to analyze the predictive value of these biological markers for response to neoadjuvant chemotherapy.Results For the primary tumor,the clinical objective response was 66.47%,29.48%SD,and 4.05% PD.Pathological complete response was found in 3 cases(1.73%).Negative nm23,and loss of Cathepsin-D were significantly predictive for an effective response to anthracycline-based neoadjuvant chemotherapy.In multivariate logistic regression analysis,only the Cathepsin-D status was found for independent predictive value.Conclusion Loss of Cathepsin-D independently predicts the response to anthracycline-based regimen.更多还原